Also, some studies tried to identify miRNAs that can predict responsiveness to treatment with trastuzumab in HER2+ BC patients, the following miRNAs (miR-940, miR-451a, miR-16-5p, and miR-17-3p) were tested by Li et al. and they discovered that the serum-based 4-miRNA signature can effectively distinguish HER2+ BC patients who are sensitive to trastuzumab from the resistant ones [50]. Here, ERBB2 is linked to breast cancer.